

# CORPORATE FACT SHEET

## Dermavant Is Committed to Fostering Unprecedented Change and Unparalleled Impact in Immuno-Dermatology

We're doing this by thinking differently, pushing the boundaries of science and partnering with providers in new ways — all with one goal: transforming the lives of millions of patients with skin diseases.

### At a Glance:

- A biopharmaceutical company
- Founded September 2015
- A subsidiary of Roivant Sciences
- U.S. operations in Long Beach, CA; Raleigh-Durham, NC; & Dallas, TX

### About Dermavant

## A Passion for Science and a Commitment to Dermatology

Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Dermavant's focus is to develop therapies that have the potential to address unmet medical needs while driving greater efficiency in research and clinical development.

The company's medical dermatology pipeline includes commercialized, late-stage and early-development product candidates that target specific unmet needs in two of the largest growing immuno-dermatology markets — plaque psoriasis and atopic dermatitis — as well as other immunological and inflammatory diseases.

Dermavant launched its first product, VTAMA® (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults in 2022. Dermavant is also developing VTAMA cream for the treatment of atopic dermatitis in adults and children as young as 2 years old. Atopic dermatitis, the most common type of eczema, affects more than 9.6 million children and 16.5 million adults in the United States.

### IMPORTANT SAFETY INFORMATION


**Indication:** VTAMA® (tapinarof) cream, 1% is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults.  
**Adverse Events:** The most common adverse reactions (incidence  $\geq$  1%) in subjects treated with VTAMA cream were folliculitis (red raised bumps around the hair pores), nasopharyngitis (pain or swelling in the nose and throat), contact dermatitis (skin rash or irritation, including itching and redness, peeling, burning, or stinging), headache, pruritus (itching), and influenza (flu).

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit [www.fda.gov/medwatch](http://www.fda.gov/medwatch) or call 1-800-FDA-1088.

## Executive Leadership Team



**Todd Zavodnick**  
Chief Executive Officer



**Chris Chapman**  
Chief Commercial Officer




**Chris Van Tuyl**  
Chief Legal Officer



**Michael Swartzburg**  
Chief Financial Officer



**David Rubenstein**  
Chief Scientific Officer



**Philip Brown**  
Chief Medical Officer



**Paul Seaback**  
Chief Technical Officer



## Dermavant Has VTAMA Cream and Other Candidates in Development Addressing:

Plaque Psoriasis in Adults, Atopic Dermatitis and Immunological and Inflammatory Diseases

PRODUCT CANDIDATE	POTENTIAL INDICATION	STAGE OF DEVELOPMENT					
		Preclinical	Phase 1	Phase 2	Phase 3	FDA Review	Commercial
<b>VTAMA® cream (DMVT-505)</b> A topical aryl hydrocarbon receptor (AhR) agonist	Plaque Psoriasis in Adults						●
<b>Tapinarof (DMVT-505)</b> A topical aryl hydrocarbon receptor (AhR) agonist	Atopic Dermatitis				●		
<b>DMVT-506</b> Next-generation aryl hydrocarbon receptor (AhR) agonist under development for multiple routes of administration	Immunological and Inflammatory Diseases	●					

**Long Beach, CA**  
3780 Kilroy Airport Way  
Suite 250  
Long Beach, CA 90806  
United States

**Dallas, TX**  
2102 E State Hwy 114  
Suite 217  
Southlake, TX 76092  
United States

**Raleigh/Durham, NC**  
3300 Paramount Pkwy  
Suite 150  
Morrisville, NC 27560  
United States

**Basel, Switzerland**  
Viaduktstrasse 8  
4051 Basel  
Switzerland